Nice read published on MedPage Today about ISA’s phase 2 trial with our lead product ISA101, led by Bonnie Glisson.

Investigators from the University of Texas MD Anderson Cancer Center assessed the potential synergy between tumor-specific vaccine ISA101 and anti–PD-1 immune checkpoint antibody (nivolumab) in patients with incurable HPV-16–positive cancer.

Here is the link to the article.